[Sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure]

Mengarelli, C; Augustovski, F; Alfie, V; Smutny, J; Latorraca, M; Pichon Riviere, A;Ciapponi, A;Alcaraz, A;Bardach, A.
Record ID 32018013924
Spanish
Original Title: Actualización - Inhibidores del cotransportador sodio/glucosa 2 (iSGLT-2) en pacientes con insuficiencia cardiaca
Authors' recommendations: Moderate-quality evidence shows that adding sodium-glucose cotransporter 2 (SGLT-2) inhibitors to standard therapy in heart failure patients with preserved or mildly reduced cardiac function >40% is likely to produce a significant net benefit by reducing hospitalization rates and slowing progression of chronic kidney disease, as well as improving quality of life. Moderate-quality evidence shows that the use of SGLT-2is added to standard therapy in patients with symptomatic heart failure and ejection fraction <40% with or without comorbidities (type 2 diabetes (T2D) and/or chronic kidney disease), yields a greater net benefit by reducing overall mortality, cardiovascular mortality, hospitalization rates and cardiorenal events. The clinical practice guidelines from different societies of cardiology (from the United States, Europe, Latin America and Argentina) recommend treatment with SGLT-2is (empagliflozin or dapagliflozin) in patients with symptomatic heart failure with comorbidities (T2D – chronic kidney failure) and in patients with heart failure with reduced function <40% not responding to standard therapy. Countries from Europe, Asia, the United States and Latin America consulted cover this technology in heart failure with or without the above mentioned comorbidities. Its cost-effectiveness was adequate in the high-income countries identified. No economic evaluations have been conducted in our country, therefore its cost-effectiveness for Argentina is uncertain.
Details
Project Status: Completed
Year Published: 2024
URL for published report: https://ets.iecs.org.ar/publication/2254
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Heart Failure
  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.